Used in pharmaceutical research as a key intermediate for synthesizing targeted protein degraders, particularly cereblon (CRBN)-based PROTACs (proteolysis-targeting chimeras). Its structure enables selective binding to cereblon E3 ubiquitin ligase, facilitating the degradation of disease-related proteins. This compound is valuable in developing treatments for cancers and other conditions involving dysregulated protein expression. It is also employed in structure-activity relationship (SAR) studies to optimize potency, selectivity, and pharmacokinetic properties of novel therapeutics.